Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092044170> ?p ?o ?g. }
- W3092044170 endingPage "153303382096214" @default.
- W3092044170 startingPage "153303382096214" @default.
- W3092044170 abstract "Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However, treatment failure is mostly due to drug resistance and the special treatment needs of different subgroups. Small molecule tyrosine kinase inhibitors can inhibit multiple targets of the human epidermal growth factor receptor family and activate PI3K/AKT, MAPK, PLC γ, ERK1/2, JAK/STAT, and other pathways affecting the expression of MDM2, mTOR, p27, and other transcription factors. This can help regulate the differentiation, apoptosis, migration, growth, and adhesion of normal cells and reverse drug resistance to a certain extent. These inhibitors can cross the blood-brain barrier and be administered orally. They have a good synergistic effect with effective drugs such as trastuzumab, pertuzumab, t-dm1, and cyclin-dependent kinase 4 and 6 inhibitors. These advantages have resulted in small-molecule tyrosine kinase inhibitors attracting attention. The new small-molecule tyrosine kinase inhibitor was investigated in multi-target anti-HER2 therapy, showed a good effect in preclinical and clinical trials, and to some extent, improved the prognosis of HER2-positive BC patients. Its use could lead to a de-escalation of treatment in some patients, possibly preventing unnecessary procedures along with the associated side effects and costs." @default.
- W3092044170 created "2020-10-15" @default.
- W3092044170 creator A5057067347 @default.
- W3092044170 creator A5068805735 @default.
- W3092044170 creator A5076359622 @default.
- W3092044170 date "2020-01-01" @default.
- W3092044170 modified "2023-10-17" @default.
- W3092044170 title "Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer" @default.
- W3092044170 cites W1986733915 @default.
- W3092044170 cites W1987576644 @default.
- W3092044170 cites W1995242599 @default.
- W3092044170 cites W1997381761 @default.
- W3092044170 cites W2006070721 @default.
- W3092044170 cites W2020387003 @default.
- W3092044170 cites W2043506695 @default.
- W3092044170 cites W2046376183 @default.
- W3092044170 cites W2047563755 @default.
- W3092044170 cites W2065725840 @default.
- W3092044170 cites W2070727232 @default.
- W3092044170 cites W2097698108 @default.
- W3092044170 cites W2098064809 @default.
- W3092044170 cites W2098716892 @default.
- W3092044170 cites W2101884133 @default.
- W3092044170 cites W2111578514 @default.
- W3092044170 cites W2118385988 @default.
- W3092044170 cites W2120661754 @default.
- W3092044170 cites W2127714076 @default.
- W3092044170 cites W2129060478 @default.
- W3092044170 cites W2129110050 @default.
- W3092044170 cites W2130727852 @default.
- W3092044170 cites W2136576452 @default.
- W3092044170 cites W2144442992 @default.
- W3092044170 cites W2149980047 @default.
- W3092044170 cites W2161422104 @default.
- W3092044170 cites W2162455270 @default.
- W3092044170 cites W2162982444 @default.
- W3092044170 cites W2170241131 @default.
- W3092044170 cites W2175026167 @default.
- W3092044170 cites W2175378170 @default.
- W3092044170 cites W2251611718 @default.
- W3092044170 cites W2264000214 @default.
- W3092044170 cites W2338611117 @default.
- W3092044170 cites W2471370097 @default.
- W3092044170 cites W2491147657 @default.
- W3092044170 cites W2560792046 @default.
- W3092044170 cites W2567701218 @default.
- W3092044170 cites W2577651608 @default.
- W3092044170 cites W2584922809 @default.
- W3092044170 cites W2613098450 @default.
- W3092044170 cites W2622102737 @default.
- W3092044170 cites W2627019357 @default.
- W3092044170 cites W2677236992 @default.
- W3092044170 cites W2745112655 @default.
- W3092044170 cites W2750532074 @default.
- W3092044170 cites W2752545514 @default.
- W3092044170 cites W2752816555 @default.
- W3092044170 cites W2759221653 @default.
- W3092044170 cites W2768980003 @default.
- W3092044170 cites W2772986641 @default.
- W3092044170 cites W2785765323 @default.
- W3092044170 cites W2789795986 @default.
- W3092044170 cites W2793039561 @default.
- W3092044170 cites W2793638865 @default.
- W3092044170 cites W2803163286 @default.
- W3092044170 cites W2806074020 @default.
- W3092044170 cites W2810342468 @default.
- W3092044170 cites W2873188210 @default.
- W3092044170 cites W2887634622 @default.
- W3092044170 cites W2889646458 @default.
- W3092044170 cites W2894868352 @default.
- W3092044170 cites W2896524087 @default.
- W3092044170 cites W2896755774 @default.
- W3092044170 cites W2897175439 @default.
- W3092044170 cites W2897683782 @default.
- W3092044170 cites W2899115689 @default.
- W3092044170 cites W2899655750 @default.
- W3092044170 cites W2914556350 @default.
- W3092044170 cites W2914757005 @default.
- W3092044170 cites W2921590809 @default.
- W3092044170 cites W2929200032 @default.
- W3092044170 cites W2936384178 @default.
- W3092044170 cites W2940050944 @default.
- W3092044170 cites W2943699531 @default.
- W3092044170 cites W2947067095 @default.
- W3092044170 cites W2947545363 @default.
- W3092044170 cites W2947742205 @default.
- W3092044170 cites W2952905991 @default.
- W3092044170 cites W2954180652 @default.
- W3092044170 cites W2969604985 @default.
- W3092044170 cites W2970779353 @default.
- W3092044170 cites W2971863214 @default.
- W3092044170 cites W2975032114 @default.
- W3092044170 cites W2982414110 @default.
- W3092044170 cites W2984731942 @default.
- W3092044170 cites W2995808512 @default.
- W3092044170 cites W2996193898 @default.
- W3092044170 cites W2999308880 @default.
- W3092044170 cites W3002857006 @default.